Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation

Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation

Michele Fornaro1, Matteo Martino1, Florinda Battaglia2, Salvatore Colicchio3, Giulio Perugi41Department of Neuroscience, Section of Psychiatry, University of Genova, Genoa, Italy; 2Center of Excellence for Biomedical Research (CEBR), Genoa, Italy; 3Department of Neurosciences, Catholic University, R...

Full description

Bibliographic Details
Main Authors:	Michele Fornaro, Matteo Martino, Florinda Battaglia, et al
Format:	Article
Language:	English
Published:	Dove Medical Press 2011-02-01
Series:	Neuropsychiatric Disease and Treatment
Online Access:	http://www.dovepress.com/increase-in-il-6-levels-among-major-depressive-disorder-patients-after-a6297

Similar Items

An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects
by: Benvenuti Marzia, et al.
Published: (2011-09-01)

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary
by: Susan G Ball, et al.
Published: (2013-01-01)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
by: Maria Rosaria Anna Muscatello, et al.
Published: (2019-10-01)

Duloxetine 60 mg for chronic low back pain: post hoc responder analysis of double-blind, placebo-controlled trials
by: Alev L, et al.
Published: (2017-07-01)

Adding 5-hydroxytryptamine receptor type 3 antagonists may reduce drug-induced nausea in poor insight obsessive-compulsive patients taking off-label doses of selective serotonin reuptake inhibitors: a 52-week follow-up case report
by: Martino Matteo, et al.
Published: (2010-12-01)

Respiratory Morbidity in Late Preterm Infants (34 weeks to 36 weeks and 6 days)
by: Cláudia Brandão Costa Correia
Published: (2019)

Continuation treatment of major depressive disorder: is there a case for duloxetine?
by: Trevor&nbsp;R Norman, et al.
Published: (2010-02-01)

Duloxetine in the treatment of major depressive disorder: an open-label study
by: Wang Fujun, et al.
Published: (2007-08-01)

Duloxetine hydrochloride
by: Mohan Bhadbhade, et al.
Published: (2009-09-01)

The role of duloxetine in the treatment of anxiety disorders
by: Domenico De Berardis, et al.
Published: (2008-07-01)

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
by: Robinson Rebecca L, et al.
Published: (2011-01-01)

Duloxetine induced hyponatremia
by: M Kulkarni
Published: (2015-01-01)

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
by: Nagao K, et al.
Published: (2013-06-01)

Role of Duloxetine in management of cervical or lumbosacral neuralgia of unknown etiology: A preliminary study
by: Digambar P Nawani, et al.
Published: (2013-01-01)

Duloxetine-Induced Hyponatremia in an Elderly Male Patient with Treatment-Refractory Major Depressive Disorder
by: Ching-Fang Sun, et al.
Published: (2019-01-01)

Is duloxetine an alternative in the treatment of osteoarthritis?
by: Joaquín Ananías, et al.
Published: (2017-10-01)

Duloxetine for the management of fibromyalgia syndrome
by: Beth A Scholz, et al.
Published: (2009-07-01)

Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data
by: Guochun Wang, et al.
Published: (2019-04-01)

The Occurrence of the Day-of-the-Week Effects on Polish and Major World Stock Markets
by: Jamróz Paweł, et al.
Published: (2014-08-01)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
by: Maneeton B, et al.
Published: (2018-08-01)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
by: Harada E, et al.
Published: (2016-01-01)

Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
by: Wohlreich Madelaine M, et al.
Published: (2005-01-01)

The Met Office Unified Model Global Atmosphere 6.0/6.1 and JULES Global Land 6.0/6.1 configurations
by: D. Walters, et al.
Published: (2017-04-01)

Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management
by: Michele Fornaro, et al.
Published: (2010-06-01)

Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
by: Jean-Pierre Oli&eacute;, et al.
Published: (2010-03-01)

A facile asymmetric synthesis of (S)-duloxetine
by: Kee-In Lee, et al.
Published: (2010-07-01)

Duloxetine in the treatment of generalized anxiety disorder
by: Alan Wright, et al.
Published: (2009-08-01)

Bleeding gums: Duloxetine may be the cause
by: Balhara YPS, et al.
Published: (2007-01-01)

Duloxetine in the management of chronic musculoskeletal pain
by: Smith EJ, et al.
Published: (2012-06-01)

Efficacy of duloxetine in achieving response and remission
by: Bauer Michael
Published: (2006-02-01)

Duloxetine in the treatment of generalized anxiety disorder
by: Trevor R Norman, et al.
Published: (2009-01-01)

Discovery and Preliminary Characterization of Translational Modulators that Impair the Binding of eIF6 to 60S Ribosomal Subunits
by: Elisa Pesce, et al.
Published: (2020-01-01)

Major changes within the vascularization of the bovine embryo 39 to 60 days gestation
by: Good, Frederick C.
Published: (2011)

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder
by: Haider M, et al.
Published: (2017-10-01)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
by: Huang J, et al.
Published: (2018-09-01)

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
by: Novick D, et al.
Published: (2016-02-01)

Interleukin-6 Gene Expression Changes after a 4-Week Intake of a Multispecies Probiotic in Major Depressive Disorder—Preliminary Results of the PROVIT Study
by: Alexandra Reiter, et al.
Published: (2020-08-01)

CWEC report week of 6.15 - 6.19.81
Published: ()

End of the day 6
by: Conley, Alston

Preliminary analysis of the accelerometric recordings of the August 24th, 2016 MW 6.0 Amatrice earthquake
by: Giovanni Lanzano, et al.
Published: (2016-11-01)